Phase 3 N=134 Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=330 Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Acanthamoeba Keratitis · Fungal Keratitis
Primary: Best Spectacle-Corrected Visual Acuity — 0.614; 0.666 logMAR
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 4 N=36 Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=18 Corneal Topographer Fluorescein Patterns
Keratoconus
Primary: Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns — 0 participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
N/A N=12 Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Keratoconus
Primary: Number of Participants With Normal Vision — 8 Participants
Phase 3 N=176 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Atopic Conjunctivitis
Primary: Percentage of Treatment Responders — 21.3; 17.2 Percentage of Patients
Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
N/A N=94 Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism
Astigmatism · Cataract
Primary: Keratometric Correction Index — 0.51 index
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
N/A N=46 Treating Contact Lens Discomfort With Orthokeratology
Dry Eye · Contact Lens Complication
Primary: Contact Lens Comfort — 22.03; 9.83 Units on a Scale — p=<0.001
Phase 4 N=94 Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface
Myopia · Refractive Error
Primary: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea) — 46.2; 44.8; 62.3 cells/mm2
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
Phase 4 N=218 Daily Wear Corneal Infiltrative Event Study
Myopia · Hyperopia · Corneal Infiltrative Events
Primary: Number of Participants Developing a Corneal Inflammatory Event (CIE) — 6; 7 participants
Phase 4 N=37 Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Neurotrophic Keratitis
Primary: Corneal Epithelial Healing — 5; 28 Participants
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
Phase 3 N=70 Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
N/A N=151 Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes
Presbyopia
Primary: Uncorrected Near Visual Acuity 20/32 or Better — 73.8 percentage of subjects
N/A N=135 Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
Keratoconus
Primary: Number of Participants With Complete Healing of Corneal Epithelial Defect at Day 3 — 20; 25 Participants
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04